View Author
scopus: 7006377517

Berneman, Z.

(Zwi Berneman)


patient fviii willebrand ddavp von willebrand disease vwd type 1 disease mutation response factor level blood vwf multimers vwf parameters study multimer group type 1 type 2 von willebrand factor table >250 erasmus univ rotterdam fviii /vwf ratio treatment jak 2v mutation michiel surgery value parameter vwf /fviii loading dose recessive marrow haemate-p diagnosis jak 2v type 2 vwd thromb haematol loading vwd patients criteria missense bone marrow features presence platelet domain thrombocythemia infusion blood group /fviii alphanate allele absence prophylaxi hemate-p rotterdam vwf deficiency european half life times vwd type 3 erasmu abo blood group deficiency plasma berneman gadisseur pattern schroyen effect recovery megakaryocyte thrombosis downloaded cat.sagepub.com type 3 vwd dosing defect




4 Most Recent Publications

Laboratory diagnosis and molecular basis of mild von willebrand disease type 1 (Article)
Michiels, J.J. Berneman, Z. Gadisseur, A. Planken, M. van der Schroyens, W. Vliet, H.H.D.M. van
2009-06-01
Managing patients with von willebrand disease type 1, 2 and 3 with desmopressin and von willebrand factor-factor VIII concentrate in surgical settings (Article)
Michiels, J.J. Vliet, H.H.D.M. van Berneman, Z. Schroyens, W. Gadisseur, A.
2009-06-01
WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders (Article)
Michiels, J.J. Raeve, H. de Hebeda, K. Lam, K.H. Berneman, Z. Schroyens, W. Schwarz, J.
2007-08-01
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients with von Willebrand disease type 1, 2 and 3 (Article)
Michiels, J.J. Vliet, H.H.D.M. van Berneman, Z. Gadisseur, A. Planken, M. van der Schroyens, W. Velden, A. van der Budde, U.
2007-01-01